Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program
The Journal of Clinical Endocrinology & Metabolism · 18.09.2023 · 108 (10) · 2653-2665
DOI: 10.1210/clinem/dgad159 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 22.03.2023. Verfasst von Philippe Backeljauw und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 4522…. Hauptthemen laut MEDLINE: Dwarfism, Pituitary, Human Growth Hormone, Turner Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Context
Despite having normal growth hormone (GH) secretion, individuals with Turner syndrome (TS) have short stature. Treatment with recombinant human GH is recommended for TS girls with short stature.
Objective
This work aimed to evaluate the effectiveness and safety of Norditropin (somatropin, Novo Nordisk) with up to 10 years of follow-up in children with TS.
Methods
Secondary analysis was conducted of Norditropin data from 2 non-interventional studies: NordiNet® IOS (NCT00960128) and the ANSWER program (NCT01009905).
Results
A total of 2377 girls with TS were included in the safety analysis set (SAS), with 1513 in the treatment-naive effectiveness analysis set (EAS). At the start of treatment, 1273 (84%) participants were prepubertal (EAS); mean (SD) age was 8.8 (3.9) years. Mean (SD) dose received at the start of GH treatment was 0.045 (0.011) mg/kg/day (EAS). Mean (SD) baseline insulin-like growth factor-1 (IGF-I) SD score (SDS) was −0.86 (1.52), and mean (SD) duration of GH treatment (SAS) was 3.8 (2.8) years. Height SDS (HSDS) increased throughout follow-up, with near-adult HSDS reached by 264 (17%) participants (mean [SD] −1.99 [0.94]; change from baseline +0.90 [0.85]). During the study, 695 (46%) participants (EAS) entered puberty at a mean (SD) age of 12.7 (1.9) years (whether puberty was spontaneous or induced was unknown). Within the SAS, mean IGF-I SDS (SD) at year 10 was 0.91 (1.69); change from baseline +1.48 (1.70). Serious adverse reactions were reported in 10 participants (epiphysiolysis [n = 3]).
Conclusion
GH-treated participants with TS responded well, without new safety concerns. Our real-world data are in agreement with previous studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229-3039, USA.
- Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool L14 5AB, UK.
- Qualiance ApS, 1663 Copenhagen V, Denmark.
- Novo Nordisk Inc, Plainsboro, NJ 08536, USA.
- Division of Pediatric Endocrinology, M Health Fairview Masonic Children's Hospital, Minneapolis, MN 55454, USA.
- Novo Nordisk Health Care AG, 8050 Zurich, Switzerland.
ORCID-Profile: Philippe Backeljauw
Förderung
- Novo Nordisk
Zitieren
APA
Backeljauw, P., Blair, J. C., Ferran, J. M., Kelepouris, N., Miller, B. S., Pietropoli, A., Polak, M., Sävendahl, L., Verlinde, F., & Rohrer, T. R. (2023). Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2653-2665. https://doi.org/10.1210/clinem/dgad159
Vancouver
Backeljauw P, Blair JC, Ferran JM, Kelepouris N, Miller BS, Pietropoli A, et al. Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2653-2665. doi:10.1210/clinem/dgad159
BibTeX
@article{Backeljauw2023,
author = {Backeljauw, Philippe and Blair, Joanne C and Ferran, Jean-Marc and Kelepouris, Nicky and Miller, Bradley S and Pietropoli, Alberto and Polak, Michel and Sävendahl, Lars and Verlinde, Franciska and Rohrer, Tilman R},
title = {Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {10},
pages = {2653--2665},
doi = {10.1210/clinem/dgad159}
}
EUVIMED